Mounjaro and Zepbound invest in Eli Lilly, ensuring a better-than-expected second quarter
INDIANAPOLIS (AP) — Eli Lilly beat expectations for the second quarter, with diabetes drug Mounjaro and its weight-loss counterpart Zepbound bringing the drugmaker sales of more than $4 billion. In…
